Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
64 Results for "
HIF-2
" in MedChemExpress (MCE) Product Catalog:
Products (64)
64 Results for "HIF-2" in MCE Product Catalog:
Cat. No.: HY-163599
CAS No.: 3034488-33-7
Target:
Research Areas:
HIF-2α-IN-12 (9) is a HIF-2α inhibitor, with an IC50 of 0.9 μM .
Cat. No.: HY-163600
CAS No.: 3034488-42-8
Target:
Research Areas:
HIF-2α-IN-13 (18) is a HIF-2α inhibitor, with an IC50 of 2.7 μM .
Cat. No.: HY-163601
CAS No.: 3033981-37-9
Target:
Research Areas:
HIF-2α-IN-14 (18) is a HIF-2α inhibitor, with an IC50 of 0.27 μM .
Cat. No.: HY-163602
CAS No.: 3033981-70-0
Target:
Research Areas:
HIF-2α-IN-15 (35) is a HIF-2α inhibitor, with an IC50 of 0.41 μM .
Cat. No.: HY-163603
CAS No.: 3033981-97-1
Target:
Research Areas:
HIF-2α-IN-16 (48) is a HIF-2α inhibitor, with an IC50 of 0.091 μM .
Cat. No.: HY-161265
Target:
Research Areas:
HIF-2α agonist 3 (Compound 14d) is an orally active HIF-2α agonist with a EC50 value of 1.78 μM. HIF-2α agonist 3 can be used in the study of renal anemia .
Cat. No.: HY-149886
CAS No.: 2648334-36-3
Target:
Research Areas:
HIF-2α-IN-9 (compound 35r) is an inhibitor ofHIF-2α. HIF-2α-IN-9 inhibits VEGF-A (IC50=305 nM), and regulates growth-promoting genes in tumor cells, reactivates macrophage-mediated tumor immunity .
Cat. No.: HY-151341
CAS No.: 2827693-99-0
Target:
Research Areas:
HIF-1/2α-IN-1 is an orally active HIF-2α inhibitor. HIF-1/2α-IN-1 inhibits HIF-2α activity with an IC50 value of 0.92 μM. HIF-1/2α-IN-1 also can decrease HIF-1α levels. HIF-1/2α-IN-1 can be used for the research of clear cell renal cell carcinoma (ccRCC) .
Cat. No.: HY-139855
CAS No.: 2685739-28-8
Target:
Research Areas:
ZG-2033 (Compound 26) is an orally active HIF-2α agonist that demonstrates nanomolar activity in luciferase reporter gene assays (EC50 = 490 nM). ZG-2033 has the effect of alleviating anemia and exhibits synergistic action with AKB-6548 (HY-101277) in anemia, and can be used in the study of renal anemia .
Cat. No.: HY-44809A
CAS No.: 1303513-80-5
Target:
Research Areas:
Izilendustat hydrochloride is a potent prolyl hydroxylase inhibitor. Izilendustat hydrochloride competitively inhibits HIFPH2 activity, blocks HIF-1α degradation, stabilizes HIF-1α and HIF-2α proteins, and upregulates downstream target gene expression. Izilendustat hydrochloride can reduce intestinal inflammation and damage, enhance the ability of phagocytes to clear pathogens, and improve ischemia-related pathological phenotypes. Izilendustat hydrochloride can be used for the research of inflammatory bowel disease, ischemic vascular disease and anemia [2].
Cat. No.: HY-183583
CAS No.: 2709068-47-1
Target:
Research Areas:
HIF-2α-IN-18 is a selective HIF-2α inhibitor with a human IC50 of 8.1 nM. HIF-2α-IN-18 binds to the HIF-2α PAS-B domain, induces conformational perturbations at the HIF-2α/ARNT dimerization interface, destabilizes the HIF-2α/ARNT heterodimer, and blocks HIF-2α-mediated transcriptional activity. HIF-2α-IN-18 inhibits hypoxia-induced expression of HIF-2α target genes EPO and SERPINE1, without inhibiting HIF-1α target genes PGK1 and PDK1. HIF-2α-IN-18 can be used for the research of clear cell renal cell carcinoma, hepatocellular carcinoma[1].
Cat. No.: HY-W470101
CAS No.: 861212-49-9
Research Areas:
HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α (HIF2α) inhibitor that binds to the PAS-B domain of HIF2α. HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70, leading to proteasomal degradation of HIF2α. HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma .
Cat. No.: HY-188081
CAS No.: 3112733-78-2
Target:
Research Areas:
YH-36400 is an orally bioavailable inhibitor of HIF-1α and HIF-2α. YH-36400 disrupts the dimerization of HIF-1α and HIF-1β and triggers proteasomal degradation, thereby inhibiting the transcriptional activities of HIF-1 and HIF-2. YH-36400 reduces the expression of PD-L1 and CD73, reprograms the tumor immune microenvironment, inhibits angiogenesis, and can be used in combination with immune checkpoint blockade therapy. YH-36400 is applicable to research related to breast cancer, lung cancer, melanoma, pancreatic cancer, colorectal cancer, prostate cancer, and head and neck squamous cell carcinoma .
Cat. No.: HY-189519
CAS No.: 1783134-96-2
Target:
Research Areas:
HIF-IN-3 is a HIF inhibitor. HIF-IN-3 blocks the dimerization of HIF-α with HIF-1β by binding to the PAS domain of HIF-α, and induces the degradation of HIF-1α and HIF-2α via the ubiquitin-proteasome pathway. HIF-IN-3 inhibits the expression of the endogenous HIF-1 target gene CA9 and the HIF-2 target gene EPO in cancer cells. HIF-IN-3 inhibits tumor growth in the BT-474 breast cancer model. HIF-IN-3 can be used for research on HIF-related tumors such as breast cancer, colorectal cancer, and head and neck squamous cell carcinoma .
Cat. No.: HY-P81153
Synonyms: Basic helix loop helix PAS protein MOP2; Basic-helix-loop-helix-PAS protein MOP2; bHLHe73; Class E basic helix-loop-helix protein 73; ECYT4; Endothelial PAS domain containing protein 1; Endothelial pas domain protein 1; Endothelial PAS domain-containing protein 1; EPAS 1; EPAS-1; EPAS1; EPAS1_HUMAN; HIF 1 alpha like factor; HIF-1-alpha-like factor; HIF-2-alpha; HIF2-alpha; HIF2A; HLF; Hypoxia inducible factor 2 alpha; Hypoxia inducible factor 2 alpha subunit; Hypoxia-inducible factor 2-alpha; Member of PAS protein 2; Member of pas superfamily 2; MOP 2; MOP2; PAS domain-containing protein 2; PASD2.
Cat. No.: HY-179647
CAS No.: 1795110-22-3
Target:
Research Areas:
ZG-2686 is a potent and selective HIF-2α agonist with an EC50 of 0.25 µM. ZG-2686 exhibits selectivity over PHD2. ZG-2686 binds to a specific internal cavity of HIF-2α, forming hydrogen bonds via structural water molecules, which stabilizes the HIF-2α/β heterodimer and enhances transcriptional activity. ZG-2686 synergizes with Vadadustat (HY-101277) to upregulate HIF-2α-dependent EPO gene expression both in vitro and in vivo. ZG-2686 can be used for the research of renal anemia .
Cat. No.: HY-108697R
CAS No.: 1672662-14-4
Research Areas:
PT2399 (Standard) is the analytical standard of PT2399 (HY-108697). This product is intended for research and analytical applications. PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo [2] .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
